Abridge was founded in 2018 with the mission of powering deeper understanding in healthcare. Our AI-powered platform was purpose-built for medical conversations, improving clinical documentation efficiencies while enabling clinicians to focus on what matters most—their patients. Our enterprise-grade technology transforms patient-clinician conversations into structured clinical notes in real-time, with deep EMR integrations. Powered by Linked Evidence and our purpose-built, auditable AI, we are the only company that maps AI-generated summaries to ground truth, helping providers quickly trust and verify the output. As pioneers in generative AI for healthcare, we are setting the industry standards for the responsible deployment of AI across health systems.

Andes is a pioneering company that integrates beneficial microorganisms into agricultural practices to enhance carbon dioxide removal from the atmosphere while promoting crop growth. Their technology allows agricultural fields to function as carbon dioxide removal mega-factories, achieving significant carbon capture at a low cost and within a short timeframe. By leveraging naturally occurring microorganisms, Andes provides a sustainable solution that not only addresses climate change but also improves soil health and agricultural productivity. The company is positioned to make a substantial impact in the carbon removal market, appealing to environmentally conscious farmers and businesses.

Aperiam Bio specializes in enhancing protein solutions through advanced algorithms that identify hyperfolding variants, significantly improving protein expression, solubility, and activity. Their innovative approach leverages computer vision to optimize protein performance, making them a leader in the biotechnology sector. The company offers a range of products including technical reagents, cosmetics, and pulmonary biologics, all designed to retain activity under challenging conditions. With a strong focus on collaboration, Aperiam Bio partners with enzyme engineers and distributors to deliver high-performing protein solutions, positioning themselves as a key player in the market.

Azitra is a clinical-stage precision dermatology company that utilizes genetic engineering and microbial technology to develop innovative therapeutics for skin diseases. The company focuses on creating engineered microbes and proteins to address various skin conditions, leveraging a proprietary microbial library of approximately 1,500 unique bacterial strains. Azitra's product pipeline includes candidates like ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor-associated rash, with plans for first-in-human trials. Their unique approach combines advanced genetic engineering with artificial intelligence to screen and identify therapeutic candidates, positioning them as pioneers in the dermatology space.

Braid Health is a digital health innovation company that develops an AI-powered diagnostic collaboration platform that improves the speed, quality, and workflow of radiologists and healthcare providers. Braid Health empowers radiologists and healthcare providers to deliver diagnoses for any patient, anywhere.

Bullseye Biosciences is a biotechnology research company that operationalizes cutting-edge directed evolution technology to develop novel therapeutics for cardiometabolic, inflammation, and oncology patients. By leveraging automation and Next Generation Sequencing, they aim to address challenging drivers of human disease, positioning themselves as a leader in the biotherapeutics space. Their world-class team focuses on translating scientific advancements into effective medicines, making them a compelling option for investors interested in innovative healthcare solutions.

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

Character is a precision medicine company focused on progressive polygenic diseases, particularly macular degeneration. By leveraging human genetics, the company aims to understand disease progression and develop targeted therapies for patients who currently lack treatment options. Character builds comprehensive clinical genomic databases to characterize patient subtypes and identify genetic drivers of diseases. Their integrated data platform enhances drug discovery and development, optimizing clinical trials and patient stratification. The company partners with various stakeholders, including patients and healthcare providers, to address significant unmet medical needs in ophthalmology.

Checkerspot is a biotechnology company that designs high-performance materials and ingredients aimed at reducing global dependence on fossil fuels. Utilizing their WING® Platform, they develop, test, and commercialize innovative products across various sectors including industrial materials, outdoor recreation, personal care, and food and nutrition. Their commitment to sustainability and performance differentiates them in the market, as they engage directly with consumers to showcase the potential of renewable, biobased products. Checkerspot's traction is evident through partnerships with leading companies and their focus on creating environmentally friendly alternatives to traditional materials.

Cirsium Biosciences is revolutionizing the gene therapy industry by developing innovative viral vector production methods using whole plants as bioreactors. Their platform addresses significant manufacturing challenges such as scalability, cost, and lead times, achieving up to a 70% reduction in manufacturing lead times for gene therapies. By utilizing a non-GMP controlled environment, they offer a cost-effective solution that simplifies the supply chain and enhances safety. With a commitment to improving global access to life-saving therapies, Cirsium is positioned as a leader in the gene therapy market, leveraging their unique plant-based production technology to meet the growing demand for viral vectors.

Curie.Bio is a founder-focused seed-stage venture capital firm that provides biotech founders with access to top drug hunters, R&D services, and capital-efficient support. With a portfolio of 20 early-stage therapeutics companies, Curie.Bio helps founders navigate the complexities of drug development, ensuring they retain agency and equity while achieving significant milestones. Their model emphasizes collaboration with experienced professionals, leveraging a vast network of CRO partnerships to enhance research capabilities and drive progress towards clinical data. This approach has proven effective, as demonstrated by their portfolio companies achieving rapid advancements and substantial funding rounds.

Cypris Materials is pioneering a sustainable, bio-inspired color industry by developing structural color technology that eliminates the need for toxic pigments and dyes. Their innovative approach allows for a full color palette using just two copolymers, significantly simplifying manufacturing and supply chain logistics. With applications across various industries including automotive, packaging, and consumer electronics, Cypris is positioned to disrupt traditional colorant markets while addressing environmental concerns. The company has gained traction through recognition in industry publications and partnerships, showcasing its commitment to sustainability and innovation in materials science.